Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide. There are no long-term effective therapies for psoriasis, so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immuno-suppressant nature and lack of understanding as to their exact mechanism of action. That’s the reason why preclinical psoriasis mouse models are needed for testing efficacy prior to clinical testing. IMAVITA is able now to propose operational psoriasis models services in this pathology.
